NSE/SUNPHARMA (NSE/SUNPHARMA)

National Stock Exchange of India: NSE/SUNPHARMA · INR

₹1,758

+6.30 (+0.4%)· Recorded snapshot

Market cap	4.2T
Revenue (ttm)	599.1B
Net income (ttm)	121B
EPS (ttm)	₹50.4
Shares out	2.4B
P/E (trailing)	34.9x
P/E (forward)	32.1x
Dividend	₹16.0 (0.91%)
Volume	1,124,878
Beta	0.14

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 599.1B
Net income (ttm): 121B
EPS (ttm): ₹50.4
P/E (trailing): 34.9x
P/E (forward): 32.1x
Market cap: 4.2T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E32.1

P25 n/aP50 n/aP75 n/a

Trailing P/E34.9

P25 n/aP50 n/aP75 n/a

ROE14.7

P25 n/aP50 n/aP75 n/a

ROIC19

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NSE/SUNPHARMA indicators

Market & fundamental data

Available fields

253

Groups with data

Currency

INR

Showing 253 of 253 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	INR
Country	India
Country code	IN
Earnings date	2026-10-30
Employees	47,000
Employees change	4,000
Employees growth	9.3%
Enterprise value	INR 3.9T
Exchange	National Stock Exchange of India
Financial currency	INR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	March
Founded	1983
In index	NIFTY50
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
ISIN number	INE044A01036
Last earnings date	2026-07-31
Last refreshed	2026-10-28
Last stock split date	2013-07-29
Last stock split type	Forward
Market cap	INR 4.2T
Next earnings date	2026-10-30
Price	INR 1,757.50
Price currency	INR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	nse/SUNPHARMA
Website	https://sunpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	33.48x
Average P/E ratio (10Y)	42.69x
Average P/E ratio (3Y)	37.38x
Average P/E ratio (5Y)	40x
Earnings yield	2.87%
EV/Earnings	32.5x
EV/EBIT	28.61x
EV/EBITDA	23.55x
EV/FCF	44.62x
EV/Sales	6.56x
FCF / EV yield	2.24%
FCF yield	2.09%
Forward P/E	32.07x
Graham number	628.47561
Graham upside	-64.24%
Industry forward P/E	33.08x
Industry P/E	38.9x
Lynch fair value	INR 757.95
Lynch upside	-56.87%
P/B ratio	5.03x
P/E ratio	34.87x
P/FCF ratio	47.87x
P/OCF ratio	33.95x
P/S ratio	7.04x
PEG ratio	2.08x
Price / tangible book value	7.01x
Price/EBITDA ratio	25.43x
Sector forward P/E	36.5x
Sector P/E	46.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	23.03%
EBITDA margin	27.68%
Effective tax rate	24.22%
FCF margin	15.07%
Gross margin	78.92%
Operating margin	23.03%
Pretax margin	26.69%
Profit margin	20.19%
Profit per employee	INR 2.6M
Profitable quarters	17
Profitable years	23
Revenue per employee	INR 12.7M
ROA	8.47%
ROA (5Y)	8.08%
ROCE	15.8%
ROE	14.72%
ROE (5Y)	13.56%
ROIC	19.01%
ROIC (5Y)	18.3%
Tax / revenue	6.46%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	16.54%
EPS growth (Q)	27.37%
EPS growth (QoQ)	7.5%
EPS growth 10Y	6.95%
EPS growth 3Y	12.82%
EPS growth 5Y	15.06%
EPS growth quarters	4
EPS growth years	5
FCF growth	-26.24%
FCF growth 3Y	45.27%
FCF growth 5Y	11.99%
Gross profit growth	12.37%
Gross profit growth (Q)	11.78%
Gross profit growth 3Y	11.74%
Gross profit growth 5Y	12.48%
Net income growth	16.62%
Net income growth (Q)	27.04%
Net income growth (QoQ)	6.66%
Net income growth 3Y	12.77%
Net income growth 5Y	15.04%
Net income growth quarters	4
Net income growth years	5
OCF growth	-11.75%
OCF growth 10Y	6.39%
OCF growth 3Y	35.8%
OCF growth 5Y	15.02%
Operating income growth	6.33%
Operating income growth (Q)	5.48%
Operating income growth 3Y	11.95%
Operating income growth 5Y	13.4%
Revenue growth	11.41%
Revenue growth (Q)	10.46%
Revenue growth (QoQ)	4.71%
Revenue growth 10Y	7.25%
Revenue growth 3Y	9.96%
Revenue growth 5Y	10.95%
Revenue growth quarters	24
Revenue growth years	8

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	INR -36.1B
Depreciation and amortization	INR 27.9B
EBIT	INR 138B
EBITDA	INR 165.8B
EPS	INR 50.40
FCF per share	INR 36.72
Financing cash flow	INR -25.1B
Free cash flow	INR 88.1B
Gross profit	INR 472.8B
Income taxes	INR 38.7B
Investing cash flow	INR -113.4B
Net borrowing	INR 17.6B
Net cash flow	INR -5B
Net income	INR 121B
Operating income	INR 138B
Revenue	INR 599.1B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	INR 348.31
Debt / EBITDA	0.28
Debt / equity	0.06
Debt / FCF	0.53
Interest coverage	37.93
Net cash (debt)	INR 288.9B
Net cash / market cap	6.85%
Net cash growth	21.59%
Net debt / EBITDA	-1.74
Net debt / equity	-0.34
Net debt / FCF	-3.28
Piotroski F-Score	5
Shareholders' equity	INR 838.8B
Tangible book value	INR 601.9B
Tangible book value per share	INR 250.86
Total cash	INR 335.2B
Total debt	INR 46.3B
WACC	5.01%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current ratio	2.82
Inventory turnover	1.09
Quick ratio	2.18
Working capital	INR 412.7B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.02%
Dividend growth	0%
Dividend growth (10Y)	31.95%
Dividend growth (3Y)	11.64%
Dividend growth (5Y)	16.36%
Dividend growth years	7
Dividend payment date	2026-08-07
Dividend payment years	26
Dividend payout frequency	Semi-Annual
Dividend per share	INR 16.00
Dividend yield	0.91%
Ex-dividend date	2026-07-07
FCF payout ratio	43.58%
Last dividend	INR 5.00
Payout ratio	31.75%
Shareholder yield	0.93%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	135.31%
10Y return CAGR	9.88%
10Y total return	156.44%
150-day SMA	INR 1,838.61
15Y price change	597.77%
15Y return CAGR	14.61%
15Y total return	673.61%
1D price change	0.36%
1M price change	-5.11%
1M total return	-5.11%
1W price change	0.83%
1W total return	0.83%
1Y price change	3.77%
1Y return CAGR	4.72%
1Y total return	4.72%
20-day SMA	INR 1,770.50
200-day SMA	INR 1,808.43
20Y price change	1,833.55%
20Y return CAGR	17.25%
20Y total return	2,310.42%
3M price change	-10.95%
3M total return	-10.95%
3Y price change	58.15%
3Y return CAGR	17.57%
3Y total return	62.52%
50-day SMA	INR 1,839.18
50-day SMA vs 200-day SMA	50over200
52-week high	INR 2,046.90
52-week high date	2026-07-31
52-week low	INR 1,583.70
52-week low date	2026-01-29
5Y price change	113%
5Y return CAGR	17.48%
5Y total return	123.79%
6M price change	1.38%
6M total return	1.65%
All-time high	INR 2,046.90
All-time high date	2026-07-31
All-time low	INR 1.65
All-time low date	1996-11-22
Average true range (ATR)	INR 33.21
Average volume	1.6M
Beta (1Y)	-0.15
Beta (2Y)	0.09
Beta (5Y)	0.14
Change from 52-week high	-14.14%
Change from 52-week low	10.97%
Change from all-time high	-14.14%
Change from all-time low	106,415.15%
Change from open	0.15%
Day's gap	0.21%
Dollar volume	INR 2B
High price	INR 1,764.00
Low price	INR 1,726.20
Monthly RSI	52.29
Open price	INR 1,754.90
Position in 52-week range	82.8%
Previous close	INR 1,751.20
Price vs 150-day SMA	-4.41%
Price vs 20-day SMA	-0.73%
Price vs 200-day SMA	-2.82%
Price vs 50-day SMA	-4.44%
Relative volume	0.7
RSI	41.34
Sharpe ratio	0.14
Sharpe ratio (3Y)	0.7
Sharpe ratio (5Y)	0.77
Sortino ratio	0.52
Sortino ratio (3Y)	1.33
Sortino ratio (5Y)	1.48
Volume	1.1M
Weekly RSI	41.95
YTD price change	2.2%
YTD total return	3.13%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.1B
Shares change (QoQ)	-0.39%
Shares change (YoY)	-0.02%
Shares held by insiders	12.01%
Shares held by institutions	28.79%
Shares outstanding	2.4B

Deeper analysis on NSE/SUNPHARMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NSE/SUNPHARMA report

Is a complete NSE/SUNPHARMA research report available?

No complete published report is available for nse/SUNPHARMA (NSE/SUNPHARMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NSE/SUNPHARMA (NSE/SUNPHARMA)

Price

Financial snapshot

Fair-value bridge

Latest news · NSE/SUNPHARMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NSE/SUNPHARMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NSE/SUNPHARMA

Frequently asked questions